scholarly article | Q13442814 |
P50 | author | Alan S Go | Q89059120 |
Daniel E. Singer | Q110881174 | ||
Margaret C. Fang | Q124660446 | ||
Elaine Hylek | Q43198009 | ||
P2093 | author name string | Yuchiao Chang | |
Lori E Henault | |||
Nancy G Jensvold | |||
P2860 | cites work | Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? | Q28166299 |
New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome | Q28183679 | ||
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial | Q28196294 | ||
Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation | Q28201331 | ||
Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation | Q28210235 | ||
Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q28213401 | ||
Validation of Clinical Classification Schemes for Predicting Stroke | Q29028208 | ||
Atrial fibrillation as an independent risk factor for stroke: the Framingham Study | Q29614200 | ||
Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators | Q33863941 | ||
A risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community: the Framingham Heart Study | Q34225539 | ||
Hemorrhagic complications of anticoagulant treatment: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy | Q35895164 | ||
Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors. | Q36101689 | ||
Increased levels of tissue plasminogen activator antigen and factor VIII activity in nonvalvular atrial fibrillation: relation to predictors of thromboembolism | Q40689539 | ||
Inaccuracy of the International Classification of Diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease. | Q41598493 | ||
Continuation of postmenopausal hormone replacement therapy in a large health maintenance organization: transdermal matrix patch versus oral estrogen therapy | Q41698761 | ||
Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study | Q41710562 | ||
Risk factors for intracranial hemorrhage in outpatients taking warfarin | Q42285556 | ||
Left atrial size and the risk of stroke and death. The Framingham Heart Study | Q43808183 | ||
Frequency and predictors of stroke death in 5,888 participants in the Cardiovascular Health Study | Q46420319 | ||
Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. | Q50861959 | ||
A method to determine the optimal intensity of oral anticoagulant therapy. | Q51058560 | ||
Left atrial volume as an index ofleft atrial size: a population-based study | Q57540337 | ||
Implications of Stroke Risk Criteria on the Anticoagulation Decision in Nonvalvular Atrial Fibrillation | Q59542153 | ||
Coagulation factors and the increased risk of stroke in nonvalvular atrial fibrillation | Q67269960 | ||
The California Automated Mortality Linkage System (CAMLIS) | Q70697716 | ||
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials | Q72030226 | ||
Markers of thrombin and platelet activity in patients with atrial fibrillation: correlation with stroke among 1531 participants in the stroke prevention in atrial fibrillation III study | Q73230310 | ||
The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators | Q73414845 | ||
Transesophageal echocardiographic correlates of thromboembolism in high-risk patients with nonvalvular atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography | Q74429767 | ||
Plasma adenosine levels and platelet activation in patients with atrial fibrillation | Q74598205 | ||
Atrial fibrillation and the prothrombotic state in the elderly: the Rotterdam Study | Q78946863 | ||
Prothrombotic activity is increased in patients with nonvalvular atrial fibrillation and risk factors for embolism | Q80557533 | ||
P433 | issue | 12 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | atrial fibrillation | Q815819 |
anticoagulation | Q63279445 | ||
P304 | page(s) | 1687-1691 | |
P577 | publication date | 2005-09-12 | |
P1433 | published in | Circulation | Q578091 |
P1476 | title | Gender differences in the risk of ischemic stroke and peripheral embolism in atrial fibrillation: the AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) study | |
P478 | volume | 112 |
Q58550785 | 2018 Korean Guideline of Atrial Fibrillation Management |
Q36974348 | A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score |
Q22306351 | ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation |
Q37496271 | AF and Venous Thromboembolism - Pathophysiology, Risk Assessment and CHADS-VASc score |
Q38724205 | Advances in understanding gender difference in cardiometabolic disease risk |
Q47247465 | Age and sex differences in atrial fibrosis among patients with atrial fibrillation |
Q53254097 | Anticoagulation in women with non-valvular atrial fibrillation in the stroke prevention using an oral thrombin inhibitor (SPORTIF) trials. |
Q51730417 | Anticoagulation in women with nonvalvular atrial fibrillation: insights from clinical trials. |
Q35752573 | Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Q37369998 | Antithrombotic therapy for the treatment of atrial fibrillation in the elderly |
Q85937915 | Are there gender differences in neurologic and psychiatric disturbances? |
Q26823099 | Arrhythmias in women |
Q36001150 | Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study |
Q47833921 | Atrial Fibrillation and Cause-Specific Risks of Pulmonary Embolism and Ischemic Stroke. |
Q33168630 | Atrial Fibrillation: The New Epidemic of the Ageing World |
Q82941599 | Atrial fibrillation |
Q44040729 | Atrial fibrillation and upper limb thromboembolectomy: a national cohort study |
Q37953464 | Atrial fibrillation catheter ablation in females: same hardware, different findings |
Q38800244 | Atrial fibrillation in women: epidemiology, pathophysiology, presentation, and prognosis |
Q30241862 | Atrial fibrillation in women: treatment |
Q91136259 | Atrial fibrillation-related stroke in women: Evidence and inequalities in epidemiology, mechanisms, clinical presentation, and management |
Q38317687 | Bridging the gender gap in atrial fibrillation |
Q37109098 | CHADS2 score has a better predictive value than CHA2DS2-VASc score in elderly patients with atrial fibrillation |
Q33820434 | Cardiac Ion Channel Regulation in Obesity and the Metabolic Syndrome: Relevance to Long QT Syndrome and Atrial Fibrillation |
Q45975729 | Cardio-embolic stroke. |
Q37346122 | Cardiovascular disease in older women: a challenge in diagnosis and treatment |
Q37495821 | Catheter Ablation of Atrial Fibrillation in Females |
Q36375674 | Cause of death in patients with atrial fibrillation admitted to French hospitals in 2012: a nationwide database study |
Q53012707 | Characteristics of patients undergoing atrial fibrillation ablation: trends over a seven-year period 1999-2005. |
Q37159030 | Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States |
Q41359271 | Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial |
Q36501853 | Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation |
Q35230096 | Comparison of the impact of atrial fibrillation on the risk of early death after stroke in women versus men |
Q47642306 | Differences and time trends in drug treatment of atrial fibrillation in men and women and doctors' adherence to warfarin therapy recommendations: a Swedish study of prescribed drugs in primary care in 2002 and 2007. |
Q38087189 | Direct thrombin and factor Xa inhibition for stroke prevention in patients with atrial fibrillation |
Q57907764 | Distribution of thromboembolism in valvular versus non-valvular atrial fibrillation |
Q37442492 | Does CHA2DS2-VASc improve stroke risk stratification in postmenopausal women with atrial fibrillation? |
Q44321220 | Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation |
Q37268102 | Effects of gender and sex steroids on ischemic injury |
Q37374524 | Epidemiology of atrial fibrillation |
Q28083655 | Epidemiology, diagnosis, and management of atrial fibrillation in women |
Q53489501 | Factors associated with control of blood pressure among elderly people diagnosed with hypertension in a rural area of South Korea: the Chungju Metabolic Disease Cohort Study (CMC study). |
Q58123839 | Female Sex as a Risk Factor for Ischemic Stroke and Systemic Embolism in Chinese Patients With Atrial Fibrillation: A Report From the China-AF Study |
Q47806738 | Female gender as a risk factor for stroke associated with atrial fibrillation |
Q44104897 | Female sex as a risk factor for stroke in atrial fibrillation: a nationwide cohort study |
Q26765963 | Gender Differences of Thromboembolic Events in Atrial Fibrillation |
Q38954398 | Gender Disparities Across the Spectrum of Advanced Cardiac Therapies: Real or Imagined? |
Q38182428 | Gender and anti-thrombotic therapy: from biology to clinical implications |
Q36784683 | Gender and tachycardia: independent modulation of platelet reactivity in patients with atrial fibrillation |
Q38155124 | Gender differences in cardiovascular therapy: focus on antithrombotic therapy and percutaneous coronary intervention |
Q48339401 | Gender differences in patients with acute ischemic stroke. |
Q51047250 | Gender differences in stroke prevention in atrial fibrillation in general practice: using the GRASP-AF audit tool. |
Q44509202 | Gender differences in the age-stratified prevalence of risk factors in Korean ischemic stroke patients: a nationwide stroke registry-based cross-sectional study |
Q39193538 | Gender differences in the effects of cardiovascular drugs |
Q38067775 | Gender disparity in cardiovascular disease: bias or biology? |
Q38623577 | Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes |
Q47390716 | Gender-Related Differences and Short-Term Outcome of Stroke: Results from a Hospital-Based Registry in Sub-Saharan Africa |
Q55450197 | Gender-related Difference in Clinical Outcome of the Patient with Atrial Fibrillation after Radiofrequency Catheter Ablation. |
Q39945146 | Gender-specific differences in stroke knowledge, stroke risk perception and the effects of an educational multimedia campaign |
Q22306361 | Guidelines for the Prevention of Stroke in Women: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association |
Q22241921 | Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association |
Q30238784 | Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association |
Q29547691 | Heart disease and stroke statistics--2014 update: a report from the American Heart Association |
Q55439684 | Impact of a History of Hypertension in Pregnancy on Later Diagnosis of Atrial Fibrillation. |
Q37322244 | Impact of proteinuria and glomerular filtration rate on risk of thromboembolism in atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study |
Q38508942 | Impact of sex and ethnicity on arrhythmic risk |
Q34100740 | Improving outpatient warfarin use for hospitalized patients with atrial fibrillation |
Q50574389 | Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. |
Q41628371 | Influence of Sex on the Association Between Epicardial Adipose Tissue and Left Atrial Transport Function in Patients With Atrial Fibrillation: A Multislice Computed Tomography Study |
Q38196305 | Is female sex a risk factor for stroke and thromboembolism in patients with atrial fibrillation? A systematic review and meta-analysis |
Q61818105 | Laminar shear stress alters endothelial KCa2.3 expression in H9c2 cells partially via regulating the PI3K/Akt/p300 axis |
Q83422982 | Lifetime risk of stroke and impact of hypertension: estimates from the adult health study in Hiroshima and Nagasaki |
Q38497702 | Management and prognosis of atrial fibrillation in the diabetic patient. |
Q47617240 | Menopausal age, postmenopausal hormone therapy and incident atrial fibrillation |
Q60960552 | Migraine with visual aura is a risk factor for incident atrial fibrillation: A cohort study |
Q28212823 | National underuse of anti-thrombotic therapy in chronic atrial fibrillation identified from digoxin prescribing |
Q38068593 | New oral anticoagulants for stroke prevention in atrial fibrillation: impact of gender, heart failure, diabetes mellitus and paroxysmal atrial fibrillation |
Q36567348 | Oral anticoagulation to reduce risk of stroke in patients with atrial fibrillation: current and future therapies |
Q37260127 | Perception of risk and knowledge of risk factors in women at high risk for stroke |
Q42525087 | Pre-eclampsia and maternal placental syndromes: an indicator or cause of long-term cardiovascular disease? |
Q46019423 | Prevalence and correlates of echocardiographic left atrial enlargement in hypertensive outpatients in clinical practice. |
Q40069787 | Prevalence and risk factors associated with stroke in middle-aged and older Chinese: A community-based cross-sectional study |
Q38011969 | Prevention of stroke in patients with atrial fibrillation: anticoagulant and antiplatelet options |
Q37853272 | Red alert for women's heart: the urgent need for more research and knowledge on cardiovascular disease in women: proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. |
Q40386721 | Revisiting sex differences in outcomes in non-valvular atrial fibrillation: a population-based cohort study |
Q45986023 | Risk factors and prognosis for clot formation on cardiac device leads. |
Q90722659 | Risk factors for severe bleeding events during warfarin treatment: the influence of sex, age, comorbidity and co-medication |
Q93141661 | Risk of ischemic stroke and utility of CHA2 DS2 -VASc score in women and men with atrial fibrillation |
Q40252006 | Risk of stroke and heart failure attributable to atrial fibrillation in middle-aged and elderly people: Results from a five-year prospective cohort study of Japanese community dwellers. |
Q46090464 | Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study |
Q33606961 | Sex Differences in Outcomes among Stroke Survivors with Non-Valvular Atrial Fibrillation in China |
Q38671483 | Sex Differences in the Use of Oral Anticoagulants for Atrial Fibrillation: A Report From the National Cardiovascular Data Registry (NCDR®) PINNACLE Registry |
Q26801284 | Sex differences in predictors of ischemic stroke: current perspectives |
Q51505075 | Sex differences in spontaneous reports on adverse bleeding events of antithrombotic treatment. |
Q82035418 | Sex differences in stroke |
Q44061441 | Sex differences in stroke prevention in atrial fibrillation in French primary care. Results of the AFIGP (Atrial Fibrillation In General Practice) database |
Q40242892 | Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation |
Q33853471 | Sex-dependent aortic valve pathology in patients with rheumatic heart disease |
Q92464329 | Sex-related differences in risk factors, type of treatment received and outcomes in patients with atrial fibrillation and acute stroke: Results from the RAF-study (Early Recurrence and Cerebral Bleeding in Patients with Acute Ischemic Stroke and Atr |
Q41364708 | Sex-related predictors for thromboembolic events after catheter ablation of atrial fibrillation: The Leipzig Heart Center AF Ablation Registry |
Q33685081 | Sex-specific responses to stroke |
Q35207701 | Statin use is associated with lower risk of atrial fibrillation in women with coronary disease: the HERS trial |
Q48110503 | Stratifying Stroke Risk in Atrial Fibrillation: Beyond Clinical Risk Scores |
Q53803663 | Stroke Prevention in Atrial Fibrillation. |
Q90182016 | Stroke and Bleeding Risk Assessments in Patients With Atrial Fibrillation: Concepts and Controversies |
Q38244278 | Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more). |
Q37714345 | Stroke in women |
Q34417168 | Stroke incidence and association with risk factors in women: a 32-year follow-up of the Prospective Population Study of Women in Gothenburg |
Q37608395 | Stroke management in women |
Q28213581 | Stroke prevention in atrial fibrillation--things can only get better |
Q34631457 | Stroke prevention in women: synopsis of the 2014 American Heart Association/American Stroke Association guideline |
Q38069194 | Stroke risk stratification scores in atrial fibrillation: current recommendations for clinical practice and future perspectives |
Q37990851 | The CHADS₂versus the new CHA2DS2-VASc scoring systems for guiding antithrombotic treatment of patients with atrial fibrillation: review of the literature and recommendations for use. |
Q38188016 | The influence of gender on heart rhythm disease. |
Q38019965 | The influence of stroke risk factors and comorbidities on assessment of stroke therapies in humans and animals |
Q37879680 | The link between atrial fibrillation and stroke in women |
Q37421352 | The net clinical benefit of warfarin anticoagulation in atrial fibrillation |
Q48870323 | Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study. |
Q34668483 | Thromboembolic event rate in paroxysmal and persistent atrial fibrillation: data from the GISSI-AF trial |
Q51408263 | Thromboembolic risk evaluation in patients with atrial fibrillation using a modified CHADS(2) scoring system. |
Q33569283 | Thrombosis and antithrombotic therapy in women |
Q38468620 | Trends in risk of stroke in patients with a hospital diagnosis of nonvalvular atrial fibrillation: National Cohort Study in Denmark, 1980-2002. |
Q48569741 | Trends in the rates of hospitalizations for acute stroke among patients over 90 years of age with atrial fibrillation in the United States: from 2005 to 2014. |
Q38083884 | Upper limb arterial thromboembolism: a systematic review on incidence, risk factors, and prognosis, including a meta-analysis of risk-modifying drugs. |
Q36951700 | Using an Atrial Fibrillation Decision Support Tool for Thromboprophylaxis in Atrial Fibrillation: Effect of Sex and Age. |
Q39121531 | Women Stroke Association Statement on Stroke |
Q34756066 | Women versus men with chronic atrial fibrillation: insights from the Standard versus Atrial Fibrillation spEcific managemenT studY (SAFETY). |
Q51140874 | [Thromboembolism risks in atrial fibrillation]. |
Search more.